GSK PLC

GSK’s EU approval of Exdensur, a new stem‑cell partnership and a £2bn share‑buyback fuel a bullish outlook, boosting revenue, pipeline breadth and shareholder returns.

GSK PLC reports Q4 2025 earnings, $11.46 B revenue growth, $0.42 EPS, new CEO plans product‑centric strategy, shares up 5.2 %.

GSK’s dual‑track strategy: China approves Trelegy Ellipta for 50 million adults, while a $2.2 billion RAPT acquisition boosts its oncology ADC platform, positioning GSK for growth.

GSK partners with Flagship Pioneering to boost biotech R&D, meets new FDA flu‑vaccine warnings, and taps accelerated review pathways for faster drug launches.

GSK’s latest regulatory wins—Shingrix prefilled syringe, bepirovirsen Phase III success, and new approvals for Exdensur and Nucala—signal a broad, growth‑focused portfolio poised to boost vaccine efficiency, advance hepatitis B cures, and expand spe…

GSK’s new Exdensur asthma drug and price‑reduction pact highlight its clinical leadership and commitment to patient‑centric care, boosting investor confidence and positioning the firm for growth in emerging biotech markets.

GSK’s new U.S. drug‑price deal and sale of Human Genome Sciences to Samsung Biologics signal a focused shift toward pricing, supply‑chain resilience and R&D investment, boosting investor confidence and positioning the pharma leader for future growth.

GSK PLC sees analyst upgrades and expanding market forecasts, including asthma spacers, prefilled syringes, and Ebola vaccine growth, boosting investor confidence.

GlaxoSmithKline’s (GSK) blood cancer treatment, Blenrep, has received FDA approval, but with a narrow label and limited indication, sparking a sharp decline in the company’s stock price and raising questions about its commercial potential.

GlaxoSmithKline Plc (GSK) is experiencing a period of strategic momentum, driven by regulatory approvals, a new CEO’s focus on commercial excellence, and a diversified global footprint, positioning the company for sustained shareholder value and pot…